Literature DB >> 6505714

Use of daunorubicin in patients with solid tumors.

D D Von Hoff.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6505714

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  4 in total

1.  Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma.

Authors:  D S Richardson; S M Kelsey; S A Johnson; M Tighe; J D Cavenagh; A C Newland
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

Review 2.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

3.  A Phase II Nonrandomised Open-Label Study of Liposomal Daunorubicin (DaunoXome) in Advanced Soft Tissue Sarcoma.

Authors:  Anne McTiernan; Jeremy Whelan; Michael Leahy; Penella J Woll
Journal:  Sarcoma       Date:  2006

4.  A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer.

Authors:  K J O'Byrne; A L Thomas; R A Sharma; M DeCatris; F Shields; S Beare; W P Steward
Journal:  Br J Cancer       Date:  2002-07-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.